| Code | CSB-RA012145MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Pulocimab, targeting KDR (Kinase Insert Domain Receptor), also known as VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2). KDR is a critical receptor tyrosine kinase that mediates vascular endothelial growth factor signaling, playing an essential role in angiogenesis, vascular permeability, and endothelial cell proliferation. This receptor is prominently expressed on vascular endothelial cells and becomes activated during pathological angiogenesis, making it a significant target in cancer biology, tumor vascularization, and various angiogenesis-related disorders including diabetic retinopathy and age-related macular degeneration.
Pulocimab represents an investigational therapeutic antibody designed to inhibit KDR-mediated signaling pathways that promote abnormal blood vessel formation. This biosimilar antibody serves as a valuable research tool for investigating VEGF/VEGFR-2 axis mechanisms, studying anti-angiogenic strategies, exploring tumor microenvironment dynamics, and evaluating vascular biology in preclinical models. It enables researchers to examine therapeutic approaches targeting pathological angiogenesis and to better understand the molecular mechanisms underlying KDR function in disease contexts.
There are currently no reviews for this product.